|
行業競爭加劇風險，買入5家，平均目標價為173.22元，高40.72元，原材料價格上漲風險。目標均價漲 AI點評：星宇股份近一個月獲得6份券商研報關注，評級理由主要包括：1）自主與新勢力客戶銷量高增助推公司產品放量；2）車燈產品升級助力單車ASP持續提升；3）收入高增有望帶動盈利能力持續改善。 |
光算谷歌外链光算谷歌营销光算爬虫池光算谷歌营销光算谷歌外鏈光算爬虫池光算谷歌推广光算谷歌外链光算谷歌营销光算谷歌外鏈光算谷歌营销https://synapse.patsnap.com/article/what-are-il-7-modulators-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-opipramol-hydrochloride-used-forhttps://synapse.patsnap.com/drug/468dfe8cef9d4a0294ada6833589f826https://synapse.patsnap.com/article/what-are-the-side-effects-of-desloratadine-citrate-disodiumhttps://synapse.patsnap.com/drug/f1f1c65c77de49b88a84ecb9ccc79b68https://synapse.patsnap.com/drug/ba273695944b44bb8c6bed64ecead35ahttps://synapse.patsnap.com/article/enliven-therapeutics-reports-positive-phase-1-trial-data-for-elvn-001-in-chronic-myeloid-leukemiahttps://synapse.patsnap.com/blog/intense-competition-and-innovative-developments-in-the-pan-kras-inhibitor-markethttps://synapse.patsnap.com/drug/aff1b94d4c324b2f9f6b9f8146818e4ehttps://synapse.patsnap.com/blog/cytonics-initiates-phase-1-trial-of-cyt-108-for-knee-osteoarthritishttps://synapse.patsnap.com/drug/4168cbe217784391b0361a8e97bb2c41https://synapse.patsnap.com/article/bioxcel-begins-phase-3-safety-trial-of-bxcl501-for-bipolar-and-schizophrenia-agitationhttps://synapse.patsnap.com/drug/1660763484474512b2ca1b29f2ca5932https://synapse.patsnap.com/article/what-are-calcium-channel-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/drug/fcc65a6595d148c09effdb5e1e0c10adhttps://synapse.patsnap.com/drug/735a9483a7974ae7bfdf57ca978cb839https://synapse.patsnap.com/drug/56a7e3b0c5ac4c25b86842015f94fb4dhttps://synapse.patsnap.com/article/what-are-vegi-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/drug/92873b7291e846e789b06f2c9d14583ahttps://synapse.patsnap.com/article/are-there-any-biosimilars-available-for-laronidasehttps://synapse.patsnap.com/drug/3bb73df1b4244679b581b5c9f70c9b9chttps://synapse.patsnap.com/article/what-are-cysteine-protease-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/drug/a80a8658fd7545ad820773b4636cd6d1https://synapse.patsnap.com/article/how-do-different-drug-classes-work-in-treating-attention-deficit-disorder-with-hyperactivityhttps://synapse.patsnap.com/article/biodexa-gets-eu-orphan-drug-status-for-erapa-in-faphttps://synapse.patsnap.com/drug/1a54720e17804942a79fbb35ac3fe398https://synapse.patsnap.com/article/what-is-the-mechanism-of-methylergonovine-maleatehttps://synapse.patsnap.com/article/health-canada-approves-gsks-ojjaara-for-anaemic-myelofibrosis-patientshttps://synapse.patsnap.com/drug/faf3d4dec1764c2cac6a42e3023c9f09https://synapse.patsnap.com/article/bi-1206-overcoming-dual-resistance-in-mantle-cell-lymphoma-through-targeting-fc%25CE%25B3riib